Pathology and Diagnosis of Ovarian Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 2231

Special Issue Editors


E-Mail Website
Guest Editor
1. Multidisciplinary Unit of Abdominopelvic Oncological Surgery (MUAPOS), Department of Obstetrics and Gynaecology, Hospital General Universitario de Castellón, 12004 Castellón, Spain
2. Oncological Surgery Research Group (OSRG), Department of Medicine, University Jaume I (UJI), 12004 Castellón, Spain
Interests: laparoscopic surgery; surgical oncology; gynecologic oncology; ovarian cancer; endometrial cancer

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Hospital del Mar, Parc de Salut Mar, 08003 Barcelona, Spain
Interests: gynecologic oncology; ovarian cancer; surgical oncology; HPV; cervical cancer; endometrial cancer

E-Mail Website
Guest Editor
Gynecologic Oncology Unit, Department of Gynecology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
Interests: gynecology; endometrial cancer; ovarian cancer, endometriosis and cervical pathology;

Special Issue Information

Dear Colleagues,

Ovarian cancer accounts for 5% of all cancers among women and causes more deaths than any other female genital tract cancer. Ovarian cancer is often diagnosed at an advanced stage, with about 70–80% of diagnoses occurring at an advanced stage; hence, for this group of patients, 5-year-survival is very low. Several prognostic factors for ovarian cancer have been studied and reported in an attempt to increase tumour-free survival, the most important and constant of these have been International Federation of Gynecology and Obstetrics (FIGO) stage, size of residual tumour after primary surgery and age at diagnosis. Other variables, such as time period, histological type and grade, performance status, preoperative CA 12.5 levels or other molecular markers appear to also be important.

In this forthcoming special Issue aim to learn about various essential aspects of the clinical and pathological diagnosis of ovarian malignant neoplasms.

Invited topics that are:

  • Risk factors for ovarian cancer;
  • Markers and new genes associated with ovarian cancer;
  • Ovarian cancer subtypes and pathological classification;
  • Identification of predictive and prognostics biomarkers;
  • Predictors of treatment responses;
  • Diagnostic tools;
  • New advances in diagnostic techniques.

Prof. Dr. Antoni Llueca
Dr. Gemma Mancebo
Prof. Dr. Antonio Gil-Moreno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • molecular markers
  • diagnostic tools
  • pathological classification
  • prognosis
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 4650 KiB  
Article
The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care
by Antoni Llueca, Sarai Canete-Mota, Anna Jaureguí, Manuela Barneo, Maria Victoria Ibañez, Alexander Neef, Enrique Ochoa, Sarai Tomas-Perez, Josep Mari-Alexandre, Juan Gilabert-Estelles, Anna Serra, Maria Teresa Climent, Carla Bellido, Nuria Ruiz, Blanca Segarra-Vidal and Maria Llueca
Diagnostics 2024, 14(17), 1868; https://doi.org/10.3390/diagnostics14171868 - 26 Aug 2024
Cited by 2 | Viewed by 1770
Abstract
Introduction: Ovarian cancer is the third most common gynaecological cancer and has a very high mortality rate. The cornerstone of treatment is complete debulking surgery plus chemotherapy. Even with treatment, 80% of patients have a recurrence. Circulating tumour DNA (ctDNA) has been shown [...] Read more.
Introduction: Ovarian cancer is the third most common gynaecological cancer and has a very high mortality rate. The cornerstone of treatment is complete debulking surgery plus chemotherapy. Even with treatment, 80% of patients have a recurrence. Circulating tumour DNA (ctDNA) has been shown to be useful in the control and follow-up of some tumours. It could be an option to define complete cytoreduction and for the early diagnosis of recurrence. Objective: We aimed to demonstrate the usefulness of ctDNA and cell-free DNA (cfDNA) as a marker of complete cytoreduction and during follow-up in patients with advanced ovarian cancer. Material and Methods: We selected 22 women diagnosed with advanced high-grade serous ovarian cancer, of which only 4 had complete records. We detected cfDNA by polymerase chain reaction (PCR), presented as ng/mL, and detected ctDNA with droplet digital PCR (ddPCR). We calculated Pearson correlation coefficients to evaluate correlations among cfDNA, ctDNA, and cancer antigen 125 (CA125), a biomarker. Results: The results obtained in the evaluation of cfDNA and ctDNA and their correlation with tumour markers and the radiology of patients with complete follow-up show disease progression during the disease, stable disease, or signs of recurrence. cfDNA and ctDNA correlated significantly with CA125. Following cfDNA and ctDNA over time indicated a recurrence several months earlier than computed tomography and CA125 changes. Conclusion: An analysis of cfDNA and ctDNA offers a non-invasive clinical tool for monitoring the primary tumour to establish a complete cytoreduction and to diagnose recurrence early. Full article
(This article belongs to the Special Issue Pathology and Diagnosis of Ovarian Cancer)
Show Figures

Figure 1

Back to TopTop